• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干扰素和威罗菲尼对揭示 Erdheim-Chester 病 - 突变的精神症状的显著疗效:病例报告。

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing -Mutated Erdheim-Chester Disease: A Case Report.

机构信息

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.

Department of Psychiatry, Dijon University Hospital, Dijon, France.

出版信息

Front Immunol. 2022 Jul 6;13:918613. doi: 10.3389/fimmu.2022.918613. eCollection 2022.

DOI:10.3389/fimmu.2022.918613
PMID:35874752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9299438/
Abstract

Erdheim-Chester disease (ECD) is a rare condition with underestimated neurological involvement. Mild psychiatric symptoms such as mood swings have been rarely described in the clinical spectrum of neuro-ECD. We here describe the first patient with psychiatric manifestations of delirium revealing ECD with neurological involvement with favorable evolution under interferon followed by BRAF inhibitor monotherapy. An 81-year-old woman was referred to the hospital because of delirium and severe cognitive impairment associated with a cerebellar syndrome. Brain magnetic resonance imaging showed "FLAIR-changes" lesions in the pons and upper cerebellum peduncles. Blood and cerebrospinal fluid (CSF) analyses showed normal results except for an elevated neopterin level in the CSF. Whole-body CT scan (FDG-PET) showed peri-nephric fat infiltration and aorta adventitia sheathing with radiotracer uptake in the pons, vessels, peri-nephric fat, and bone lesions, which was characteristic of ECD. The diagnosis was confirmed on perirenal tissue biopsy, which also showed a mutation. Treatment with interferon resulted in the resolution of delirium, and treatment with BRAF inhibitor subsequently resulted in a partial remission of all active sites. This case highlights that delirium can be the first manifestation of neurodegenerative ECD. ECD should be screened in unexplained psychiatric features as interferon and targeted therapy appear to be effective in this situation.

摘要

厄尔-道伊姆-切斯特病(ECD)是一种罕见的疾病,其神经受累被低估了。轻度精神症状,如情绪波动,在神经 ECD 的临床谱中很少被描述。我们在这里描述了首例以谵妄为表现的精神症状的患者,该患者患有 ECD,伴有神经受累,经干扰素治疗后病情得到改善,随后接受 BRAF 抑制剂单药治疗。一名 81 岁女性因谵妄和严重认知障碍伴小脑综合征而被收入院。脑磁共振成像显示桥脑和上小脑脚的“FLAIR 改变”病变。血液和脑脊液(CSF)分析除了 CSF 中升高的新蝶呤水平外,结果均正常。全身 CT 扫描(FDG-PET)显示肾周脂肪浸润和主动脉外膜鞘,桥脑、血管、肾周脂肪和骨病变摄取放射性示踪剂,这是 ECD 的特征。肾周组织活检证实了这一诊断,该活检还显示存在 突变。干扰素治疗导致谵妄消退,BRAF 抑制剂治疗随后导致所有活跃部位部分缓解。该病例强调,谵妄可能是神经退行性 ECD 的首发表现。在无法解释的精神特征中应筛查 ECD,因为干扰素和靶向治疗在这种情况下似乎是有效的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/41f2c7963e4e/fimmu-13-918613-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/506854268893/fimmu-13-918613-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/9df21480cba0/fimmu-13-918613-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/41f2c7963e4e/fimmu-13-918613-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/506854268893/fimmu-13-918613-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/9df21480cba0/fimmu-13-918613-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5087/9299438/41f2c7963e4e/fimmu-13-918613-g003.jpg

相似文献

1
Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing -Mutated Erdheim-Chester Disease: A Case Report.干扰素和威罗菲尼对揭示 Erdheim-Chester 病 - 突变的精神症状的显著疗效:病例报告。
Front Immunol. 2022 Jul 6;13:918613. doi: 10.3389/fimmu.2022.918613. eCollection 2022.
2
Hypoalphalipoproteinemia and BRAF Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.低α脂蛋白血症和 BRAF 突变是 Erdheim-Chester 病主动脉浸润的主要预测因子。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.
3
An effective treatment in Erdheim Chester disease: vemurafenib: a case report.厄德海姆-切斯特病的有效治疗:威罗非尼:一例报告。
J Med Case Rep. 2023 Oct 12;17(1):426. doi: 10.1186/s13256-023-04153-z.
4
Vemurafenib as first-line therapy in -V600E-mutant Erdheim-Chester disease with CNS involvement.维莫非尼作为伴有中枢神经系统受累的-V600E突变型 Erdheim-Chester 病的一线治疗药物。
BMJ Case Rep. 2019 Nov 19;12(11):e228280. doi: 10.1136/bcr-2018-228280.
5
Multisystem Erdheim-Chester disease presenting with pericardial effusion confirmed by the effusion cytology specimen.多发系统 Erdheim-Chester 病伴发的心包积液,经积液细胞学标本证实。
Cardiovasc Pathol. 2024 May-Jun;70:107625. doi: 10.1016/j.carpath.2024.107625. Epub 2024 Feb 28.
6
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.维莫非尼治疗 BRAF V600 突变型 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症:来自组织学独立、开放标签 VE-BASKET 研究的数据分析。
JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.
7
[Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].[厄尔德海姆-切斯特病——一种具有不寻常肾脏受累的组织细胞多系统疾病]
Internist (Berl). 2020 Sep;61(9):969-979. doi: 10.1007/s00108-020-00849-2.
8
BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.中枢神经系统(CNS-JXG)幼年黄色肉芽肿家族性肿瘤中的 BRAF V600E 突变:包括小儿神经鞘黏液瘤病在内的修订诊断算法。
Acta Neuropathol Commun. 2019 Nov 4;7(1):168. doi: 10.1186/s40478-019-0811-6.
9
The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.组织细胞增多症厄尔布-切斯特病是一种炎性髓系肿瘤。
Expert Rev Clin Immunol. 2015;11(9):1033-42. doi: 10.1586/1744666X.2015.1060857. Epub 2015 Jul 21.
10
Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF mutation. Erdheim-Chester 病(ECD)的腹部受累:MRI 和 CT 影像学表现及其与 BRAF 突变的关系。
Eur Radiol. 2018 Sep;28(9):3751-3759. doi: 10.1007/s00330-018-5326-1. Epub 2018 Mar 19.

引用本文的文献

1
Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.组织细胞增多症中的分子突变:基因改变的全面综述
Mol Biotechnol. 2025 Feb;67(2):438-455. doi: 10.1007/s12033-024-01072-2. Epub 2024 Feb 20.

本文引用的文献

1
Rosai-Dorfman-Destombes disease of the nervous system: a systematic literature review.神经系统 Rosai-Dorfman-Destombes 病:系统文献回顾。
Orphanet J Rare Dis. 2022 Mar 2;17(1):92. doi: 10.1186/s13023-022-02220-0.
2
Histiocytosis and the nervous system: from diagnosis to targeted therapies.组织细胞增生症与神经系统:从诊断到靶向治疗。
Neuro Oncol. 2021 Sep 1;23(9):1433-1446. doi: 10.1093/neuonc/noab107.
3
Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases.脑脊液中新蝶呤作为神经炎症性疾病的生物标志物。
Sci Rep. 2020 Oct 26;10(1):18291. doi: 10.1038/s41598-020-75500-z.
4
Central nervous system involvement in Erdheim-Chester disease: An observational cohort study.中枢神经系统受累的 Erdheim-Chester 病:一项观察性队列研究。
Neurology. 2020 Nov 17;95(20):e2746-e2754. doi: 10.1212/WNL.0000000000010748. Epub 2020 Sep 4.
5
Longitudinally Extensive Spinal Cord Lesion in Erdheim-Chester Disease.厄德里希-切斯特病中的纵向广泛脊髓病变
JAMA Neurol. 2020 Nov 1;77(11):1446-1447. doi: 10.1001/jamaneurol.2020.2460.
6
Neurological manifestations of Erdheim-Chester Disease.脑白质营养不良的神经表现。
Ann Clin Transl Neurol. 2020 Apr;7(4):497-506. doi: 10.1002/acn3.51014. Epub 2020 Mar 29.
7
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.骨硬化性嗜酸性肉芽肿:分子时代下的评估、诊断和治疗的共识建议。
Blood. 2020 May 28;135(22):1929-1945. doi: 10.1182/blood.2019003507.
8
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.神经和肿瘤学特征的 Erdheim-Chester 病:一个 30 例系列。
Neuro Oncol. 2020 Jul 7;22(7):979-992. doi: 10.1093/neuonc/noaa008.
9
Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study.中枢神经系统感染患者的脑脊液生物标志物:一项回顾性研究。
CNS Spectr. 2020 Jun;25(3):402-408. doi: 10.1017/S1092852919000981. Epub 2019 May 27.
10
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.用于 Erdheim-Chester 病患者的患者报告症状评估的量表。
Blood Adv. 2019 Apr 9;3(7):934-938. doi: 10.1182/bloodadvances.2018030502.